Trillium Asset Management LLC Acquires New Shares in TransMedics Group, Inc. $TMDX

Trillium Asset Management LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 41,577 shares of the company’s stock, valued at approximately $2,762,000.

A number of other institutional investors also recently bought and sold shares of TMDX. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the third quarter valued at $29,000. North Star Investment Management Corp. acquired a new stake in TransMedics Group in the 1st quarter valued at about $30,000. Ascentis Independent Advisors acquired a new stake in TransMedics Group in the 1st quarter valued at about $30,000. Allworth Financial LP raised its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Finally, State of Wyoming acquired a new position in TransMedics Group during the second quarter worth about $31,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on TMDX shares. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. UBS Group cut their price objective on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Weiss Ratings cut TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. Stifel Nicolaus boosted their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Finally, Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $124.18.

TransMedics Group Trading Up 4.3%

Shares of TransMedics Group stock opened at $94.77 on Friday. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The business’s fifty day moving average is $77.49 and its two-hundred day moving average is $95.32. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a market cap of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.92 EPS. Analysts anticipate that TransMedics Group, Inc. will post 1.47 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.